ScholarLens Back to search
2013•Scandinavian Journal of Infectious DiseasesRequires access

Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: A case report

Kristina Langholz Kristensen, Ulrik Bak Dragsted

Open publisher page 10 citations

Abstract

Kristina Langholz Kristensen*a & Ulrik Bak Dragstedaa From the Department of Internal Medicine, Roskilde Hospital, Roskilde, DenmarkCorrespondence: K. Langholz Kristensen, Department of Internal Medicine, Roskilde Hospital, Køgevej 7–13, DK-4000 Roskilde, Denmark. Tel: + 45 24 42 69 70. E-mail: Kristina.langholz@gmail.comAbstractThe ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.

About this research paper

What this paper is about

Kristina Langholz Kristensen*a & Ulrik Bak Dragstedaa From the Department of Internal Medicine, Roskilde Hospital, Roskilde, DenmarkCorrespondence: K. Langholz Kristensen, Department of Internal Medicine, Roskilde Hospital, Køgevej 7–13, DK-4000 Roskilde, Denmark. Tel: + 45 24 42 69 70. E-mail: Kristina.langholz@gmail.comAbstractThe ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Kristina Langholz Kristensen*a & Ulrik Bak Dragstedaa From the Department of Internal Medicine, Roskilde Hospital, Roskilde, DenmarkCorrespondence: K. Langholz Kristensen, Department of Internal Medicine, Roskilde Hospital, Køgevej 7–13, DK-4000 Roskilde, Denmark. Tel: + 45 24 42 69 70. E-mail: Kristina.langholz@gmail.comAbstractThe ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.

Key concepts: Primaquine, Malaria, Plasmodium vivax, Vivax malaria, Medicine, Drug resistance, Negative therapeutic reaction, Virology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: A case report — Research Paper | ScholarLens